EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO / deSUMOylation in cerebral ischemia–reperfusion injury

Xiangyu Chen, Tong Yang, Yue Zhou, Zhigang Mei iD, Wenli Zhang iD

CNS Neuroscience & Therapeutics · 2024-04 · 30 (4)

DOI: 10.1111/cns.14725 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 14.04.2024. Verfasst von Xiangyu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Col…. Hauptthemen laut MEDLINE: Mitochondrial Dynamics, Neuroblastoma, Pyrazines, Saponins. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Young Qihuang Scholar Support Project of National Administration of Traditional Chinese Medicine, the Project of Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Astragaloside IV (AST IV) and ligustrazine (Lig), the main ingredients of Astragali Radix and Chuanxiong Rhizoma respectively, have demonstrated significant benefits in treatment of cerebral ischemia ‐reperfusion injury (CIRI); however, the mechanisms underlying its benificial effects remain unclear. SUMO‐1ylation and deSUMO‐2/3ylation of dynamin‐related protein 1 (Drp1) results in mitochondrial homeostasis imbalance following CIRI, which subsequently aggravates cell damage. This study investigates the mechanisms by which AST IV combined with Lig protects against CIRI, focusing on the involvement of SUMOylation in mitochondrial dynamics.

Methods

Rats were administrated AST IV and Lig for 7 days, and middle cerebral artery occlusion was established to mimic CIRI. Neural function, cerebral infarction volume, cerebral blood flow, cognitive function, cortical pathological lesions, and mitochondrial morphology were measured. SH‐SY5Y cells were subjected to oxygen–glucose deprivation/reoxygenation (OGD/R) injury. Mitochondrial membrane potential and lactic dehydrogenase (LDH), reactive oxygen species (ROS), and adenosine triphosphate (ATP) levels were assessed with commercial kits. Moreover, co‐immunoprecipitation (Co‐IP) was used to detect the binding of SUMO1 and SUMO2/3 to Drp1. The protein expressions of Drp1, Fis1, MFF, OPA1, Mfn1, Mfn2, SUMO1, SUMO2/3, SENP1, SENP2, SENP3, SENP5, and SENP6 were measured using western blot.

Results

In rats with CIRI, AST IV and Lig improved neurological and cognitive functions, restored CBF, reduced brain infarct volume, and alleviated cortical neuron and mitochondrial damage. Moreover, in SH‐SY5Y cells, the combination of AST IV and Lig enhanced cellular viability, decreased release of LDH and ROS, increased ATP content, and improved mitochondrial membrane potential. Furthermore, AST IV combined with Lig reduced the binding of Drp1 with SUMO1, increased the binding of Drp1 with SUMO2/3, suppressed the expressions of Drp1, Fis1, MFF, and SENP3, and increased the expressions of OPA1, Mfn1, Mfn2, SENP1, SENP2, and SENP5. SUMO1 overexpression promoted mitochondrial fission and inhibited mitochondrial fusion, whereas SUMO2/3 overexpression suppressed mitochondrial fission. AST IV combined with Lig could reverse the effects of SUMO1 overexpression while enhancing those of SUMO2/3 overexpression.

Conclusions

This study posits that the combination of AST IV and Lig has the potential to reduce the SUMO‐1ylation of Drp1, augment the SUMO‐2/3ylation of Drp1, and thereby exert a protective effect against CIRI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitochondrial DynamicsNeuroblastomaPyrazinesSaponinsTriterpenesHumansAnimalsRatsReactive Oxygen SpeciesAdenosine TriphosphateDynaminsCysteine Endopeptidases

Stichwörter der Autor:innen

Astragaloside IVLigustrazineSUMOylationcerebral ischemia–reperfusion injurymitochondrial dynamics

Substanzen

astragaloside AtetramethylpyrazineReactive Oxygen SpeciesAdenosine TriphosphateDynaminsSENP6 protein, humanCysteine EndopeptidasesSENP3 protein, humanPyrazinesSaponins

Autor:innen und Institutionen

  • Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, College of Integrated Traditional Chinese and Western Medicine, Hunan Uni…
  • The First Clinical Medicine School of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
  • Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Changsha, Hunan, China.
  • Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, College of Medicine and Health Sciences, China Three Gorges University, Yichang, Hubei, China.
  • School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, China.

ORCID-Profile: Zhigang Mei, Wenli Zhang

Förderung

  • the National Natural Science Foundation of China
  • the Young Qihuang Scholar Support Project of National Administration of Traditional Chinese Medicine
  • the Project of Natural Science Foundation of Hunan Province
  • the fund for Youth Top Talent Project of Hubei Provincial Health and Family Planning Commission
  • National Natural Science Foundation of China

Zitieren

APA

Chen, X., Yang, T., Zhou, Y., Mei, Z., & Zhang, W. (2024). Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO / deSUMOylation in cerebral ischemia–reperfusion injury. CNS Neuroscience & Therapeutics, 30(4). https://doi.org/10.1111/cns.14725

Vancouver

Chen X, Yang T, Zhou Y, Mei Z, Zhang W. Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO / deSUMOylation in cerebral ischemia–reperfusion injury. CNS Neuroscience & Therapeutics. 2024;30(4). doi:10.1111/cns.14725

BibTeX
@article{Chen2024,
  author = {Chen, Xiangyu and Yang, Tong and Zhou, Yue and Mei, Zhigang and Zhang, Wenli},
  title = {Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO / deSUMOylation in cerebral ischemia–reperfusion injury},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  volume = {30},
  number = {4},
  doi = {10.1111/cns.14725}
}
Kostenlos starten →